Treatment of cancer

Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

Retrieved on: 
Tuesday, June 15, 2021
Branches of biology, Biology, Clinical medicine, Cell biology, Cancer immunotherapy, Immune system, Virotherapy, Medicinal chemistry, Immunotherapy, Macrophage, Treatment of cancer, Therapy

The new patents title is COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT, and is expected to provide added intellectual property protection for therapeutic compositions of AllocetraTMand CAR-T immunotherapies for inhibition or reduction ofcytokine storms associated with CAR-T therapies for cancer.

Key Points: 
  • The new patents title is COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT, and is expected to provide added intellectual property protection for therapeutic compositions of AllocetraTMand CAR-T immunotherapies for inhibition or reduction ofcytokine storms associated with CAR-T therapies for cancer.
  • Oren Hershkovitz, PhD, CEO of Enlivex, stated, We are pleased to have this patent granted in Europe, which adds to existing AllocetraTM patents in various countries around the world.
  • Specifically, this new patent further strengthens our existing intellectual property portfolio covering the use of AllocetraTM for cancer therapy.
  • AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.

Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

Retrieved on: 
Tuesday, June 15, 2021
Treatment of cancer, Oncogenes, Oncolytics Biotech

(RELATED: MHRA sheds light on pathway to accelerate R&D ,Regulatory Focus24 December 2020).

Key Points: 
  • (RELATED: MHRA sheds light on pathway to accelerate R&D ,Regulatory Focus24 December 2020).
  • Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.
  • Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
  • In collaboration with our academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trial in adult ALL and B-NHL.

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Retrieved on: 
Thursday, June 10, 2021
Life sciences, Biotechnology, Health sciences, Specialty drugs, Treatment of cancer, Biopharmaceutical, Sarcoma, Cancer

Details on accessing the event can be found in the Investors section of Salarius website under Events and Presentations, http://investors.salariuspharma.com/events-and-presentations/upcoming-ev... .

Key Points: 
  • Details on accessing the event can be found in the Investors section of Salarius website under Events and Presentations, http://investors.salariuspharma.com/events-and-presentations/upcoming-ev... .
  • The Virtual KOL & Investor Event will feature speakers from the Salarius management team and experts in the fields of epigenetics, sarcomas, and hematological cancers.
  • Whetstine, Chawla and Bhalla participate in our Virtual KOL & Investor Event and look forward to their insight on these and other topics important to Salarius and the treatment of cancer.
  • Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options.

Cancer Treatment Centers of America Atlanta Launches Women’s Cancer Center

Retrieved on: 
Monday, June 7, 2021
Oncology, Health, Consumer, Hospitals, Women, General Health, Health sciences, Boca Raton, Florida, Cancer Treatment Centers of America, Natural sciences, Applied sciences, CTCA, Treatment of cancer, Therapy, Cancer, Radiation therapy, Oncology

Cancer Treatment Centers of America (CTCA) is a national oncology network of hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship.

Key Points: 
  • Cancer Treatment Centers of America (CTCA) is a national oncology network of hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy and advancements in precision medicine with supportive therapies to manage side effects and enhance quality of life during treatment and into survivorship.
  • CTCA publishes treatment results bi-annually including patient experience, length of life, quality of life, patient safety and quality of care.
  • CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research.
  • CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country.

Elekta's new strategy to focus on growth and access to radiation therapy

Retrieved on: 
Monday, June 7, 2021
Health sciences, Medicine, Applied sciences, Medical physics, Radiation therapy, Radioactivity, Radiobiology, Treatment of cancer, Therapy, Cancer

Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.

Key Points: 
  • Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.
  • Although these countries comprise 85 percent of the global population, they only have 40 percent of the total installed base of radiation therapy devices.
  • Elekta's new strategy will also address improving radiation therapy technology and advanced techniques such as hypofractionation and adaptive treatments.
  • The Access 2025 strategy is built on four pillars: innovation, partner integration, customer focus and driving adoption of radiation therapy across the globe, reflecting Elekta's vision to create a world where everyone has access to the best cancer care.

Elekta's new strategy to focus on growth and access to radiation therapy

Retrieved on: 
Monday, June 7, 2021
Health sciences, Medicine, Applied sciences, Medical physics, Radiation therapy, Radioactivity, Radiobiology, Treatment of cancer, Therapy, Cancer

Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.

Key Points: 
  • Gustaf Salford said that he wanted to see more than 300 million people with cancer gaining access to radiation therapy, an integral part of most cancer treatments.
  • Although these countries comprise 85 percent of the global population, they only have 40 percent of the total installed base of radiation therapy devices.
  • Elekta's new strategy will also address improving radiation therapy technology and advanced techniques such as hypofractionation and adaptive treatments.
  • The Access 2025 strategy is built on four pillars: innovation, partner integration, customer focus and driving adoption of radiation therapy across the globe, reflecting Elekta's vision to create a world where everyone has access to the best cancer care.

NOXXON Announces Positive Results From Second Cohort in Phase 1/2 NOX-A12 Brain Cancer Trial

Retrieved on: 
Tuesday, June 8, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Cancer, Health, Medicine, Oncology, Noxxon Pharma, Brain tumor, Glioblastoma, Treatment of cancer, Blastoma, Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Cancer, Health, Clinical medicine, Oncology, Noxxon Pharma, Brain tumor, Glioblastoma, Treatment of cancer, Blastoma

NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today positive results from the second cohort in its Phase 1/2 study of NOX-A12 in combination with radiotherapy in patients with brain cancer (Glioblastoma Multiforme).

Key Points: 
  • NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today positive results from the second cohort in its Phase 1/2 study of NOX-A12 in combination with radiotherapy in patients with brain cancer (Glioblastoma Multiforme).
  • The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients.
  • In three of the six patients, smaller satellite lesions that were present before therapy around the primary tumor completely disappeared.
  • Enrolment of patients in the third cohort has been completed and we expect results from the last cohort in Q4 2021, commented Aram Mangasarian, CEO of NOXXON.

PolyU develops biomimetic nanosheet for cancer therapy and imaging

Retrieved on: 
Monday, May 31, 2021
Medicine, Clinical medicine, Health sciences, Medical physics, Cancer treatments, Antineoplastic drugs, Oncology, Oncothermia, Photothermal therapy, Therapy, Treatment of cancer, Radiation therapy

The newly developed biomimetic nanomaterials developed by PolyU are part of our endeavours in fighting against cancer.

Key Points: 
  • The newly developed biomimetic nanomaterials developed by PolyU are part of our endeavours in fighting against cancer.
  • By integrating two emerging cancer therapies, immunotherapy and photothermal therapy, with three imaging modalities for the first time, the novel biomimetic nanomaterials provide a practical design blueprint for the development of a new generation of cancer theranostics agents which have high targeting ability, efficacy and safety."
  • New cancer treatments emerge since conventional cancer treatments like surgical therapy, chemotherapy and radiotherapy have different limitations and side effects.
  • The biomimetic nanosheets developed by our team allow us to combine these two methods for synergistic therapy.

PolyU develops biomimetic nanosheet for cancer therapy and imaging

Retrieved on: 
Monday, May 31, 2021
Medicine, Clinical medicine, Health sciences, Medical physics, Cancer treatments, Antineoplastic drugs, Oncology, Oncothermia, Photothermal therapy, Therapy, Treatment of cancer, Radiation therapy

The newly developed biomimetic nanomaterials developed by PolyU are part of our endeavours in fighting against cancer.

Key Points: 
  • The newly developed biomimetic nanomaterials developed by PolyU are part of our endeavours in fighting against cancer.
  • By integrating two emerging cancer therapies, immunotherapy and photothermal therapy, with three imaging modalities for the first time, the novel biomimetic nanomaterials provide a practical design blueprint for the development of a new generation of cancer theranostics agents which have high targeting ability, efficacy and safety."
  • New cancer treatments emerge since conventional cancer treatments like surgical therapy, chemotherapy and radiotherapy have different limitations and side effects.
  • The biomimetic nanosheets developed by our team allow us to combine these two methods for synergistic therapy.

Oncotech develops AI-powered real-time mobile cancer screening and detection system

Retrieved on: 
Thursday, May 27, 2021
Medicine, Health, Clinical medicine, Hereditary cancers, Histopathology, Prostate cancer, Breast cancer, Cancer, Oncology, Treatment of cancer, Screening, War on Cancer

Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.

Key Points: 
  • Developed by Oncotech Nordic AB , Ophtascan is a mobile in-real-time detection system of pre-cancerous and all four levels of cancer conditions and targeted oncological diseases in the human body.
  • The process is quick, on demand, cost effective - and does not overload the public health care diagnostic system unnecessarily, hence eliminating patient cancer screening waiting lists.
  • "Conditions currently clinically validated and screened include lung cancer, liver cancer, breast cancer, uterine cancer, and prostate cancer."
  • The Therapeutic R&D and focus is on Diagnostics (mobile in-time cancer screening technology) and cancer treatment Therapies (breast, uterus, lung, prostate, pancreas, liver and neuroblastoma).